ORKA (Oruka Therapeutics) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Change In Receivables?

Oruka Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Oruka Therapeutics's Accounts Receivable stayed the same from . 20 to Dec. 2024 .

Oruka Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means Oruka Therapeutics's Accounts Receivable stayed the same from . 20 to Dec. 2024 .

Oruka Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oruka Therapeutics's liquidation value for the six months ended in Dec. 2024 was $361.85 Mil.

Oruka Therapeutics Change In Receivables Historical Data

The historical data trend for Oruka Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Change In Receivables Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Change In Receivables

Oruka Therapeutics Semi-Annual Data
	Dec24
Change In Receivables	-

Oruka Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics (NAS:ORKA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Oruka Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Oruka Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Oruka Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	375.648	-	13.798	+	0.75 * 0	+	0.5 * 0
=	361.85

Oruka Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.